CanSino Biologics (HKG:6185) received Chinese regulatory approval for its infant combination vaccine, according to a Hong Kong bourse filing Sunday.
Shares of the firm gained over 1% in morning trade Monday.
China's National Medical Products Administration approved the company's DTcP vaccine Tripecia, which protects from diphtheria, tetanus, and pertussis for infants below 2 years old.
CanSino said its vaccine is the first of its kind to be launched in China for infants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.